About Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (B3GAT1) is a protein
from Homo sapiens identified by UniProt accession
Q9P2W7, 334 residues long.
MolForge cross-references it against 0 known binders and
475 disease associations.
Target properties
| Protein name | Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 |
| UniProt accession | Q9P2W7 |
| Gene | B3GAT1 |
| Organism | Homo sapiens |
| Length | 334 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (475)
Diseases linked to this target (Open Targets).
- alkaline phosphatase measurement · score 0.42
- prostate carcinoma · score 0.35
- body fat percentage · score 0.29
- insomnia measurement · score 0.29
- N-glycan measurement · score 0.28
- fat body mass · score 0.26
- Age-related cataract · score 0.26
- body mass index · score 0.21
- lean body mass · score 0.21
- neurofibrillary tangles measurement · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P2W7-F1 | alphafold | PREDICTED | 86.83 | — |
Amino-acid sequence (334 residues)
MPKRRDILAI VLIVLPWTLL ITVWHQSTLA PLLAVHKDEG SDPRRETPPG ADPREYCTSD RDIVEVVRTE YVYTRPPPWS DTLPTIHVVT PTYSRPVQKA ELTRMANTLL HVPNLHWLVV EDAPRRTPLT ARLLRDTGLN YTHLHVETPR NYKLRGDARD PRIPRGTMQR NLALRWLRET FPRNSSQPGV VYFADDDNTY SLELFEEMRS TRRVSVWPVA FVGGLRYEAP RVNGAGKVVG WKTVFDPHRP FAIDMAGFAV NLRLILQRSQ AYFKLRGVKG GYQESSLLRE LVTLNDLEPK AANCTKILVW HTRTEKPVLV NEGKKGFTDP SVEI
Explore Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets